Drugs / Novaferon
Novaferon
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04380545 | Jan 2021 → Feb 2028 expected | fibrolamellar hepatocellular carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02455596 | May 2015 → Oct 2016 | neuroendocrine neoplasm | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02068131 | Feb 2014 → Nov 2016 | colorectal cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01386242 | May 2011 → May 2013 | colorectal cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT05017714 | Aug 2021 → Apr 2022 | COVID-19 | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04669015 | Jun 2021 → Aug 2022 | COVID-19 | Genova Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT04708158 | Mar 2021 → Apr 2023 | COVID-19 | Genova Inc. | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT04418219 Background | Dec 2020 → Jan 2023 | female breast carcinoma, invasive breast carcinoma | Thomas Jefferson University | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT05172037 Comparator | Oct 2021 → Mar 2022 | COVID-19 | Genova Inc. | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novaferon | “BACKGROUND: To observe the efficacy, safety, and optimal dosage of recombinant antitumor and antivirus protein (Novaferon) in treating patients with metastatic colorectal...” PMID 25926350 ↗ Apr 20157“Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.” NCT05017714 ↗ “Novaferon, Recombinant IFN Alfa-2b-like Protein” NCT04418219 ↗ |
| Known as | Brand name: Novaferon | “Brand name: Novaferon” NCT01386242 ↗ |
| Known as | Nova (artificial interferon) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650410 ↗ |
| Known as | recombinant antitumor and antivirus protein | “BACKGROUND: To observe the efficacy, safety, and optimal dosage of recombinant antitumor and antivirus protein (Novaferon) in treating patients with metastatic colorectal...” PMID 25926350 ↗ Apr 2015 |
| Known as | Recombinant IFN Alfa-2b-like Protein | “Novaferon, Recombinant IFN Alfa-2b-like Protein” NCT04418219 ↗ |
| Known as | Recombinant Interferon Alpha 2b-like Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04380545 ↗ |
| Modality | Protein / enzyme biologic | “recombinant antitumor and antivirus protein (Novaferon)” PMID 25926350 ↗ Apr 2015 |
| Route | Intramuscular | “20μg, im, twice per week after 2 weeks” NCT01386242 ↗ |